Biosimilar Basics News Today

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.

Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and reference drugs.